Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Publication year range
1.
Nutr Metab Cardiovasc Dis ; 24(1): 10-7, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23806740

ABSTRACT

BACKGROUND AND AIM: The aim of this study was to compare the use of insulin glargine and intermediate/long-acting human insulin (HI) in relation to the incidence of complications in diabetic patients. METHODS AND RESULTS: A population-based cohort study was conducted using administrative data from four local health authorities in the Abruzzo Region (900,000 inhabitants). Diabetic patients without macrovascular diseases and treated with either intermediate/long-acting HI or glargine were followed for 3-years; the incidence of diabetic (macrovascular, microvascular and metabolic) complications was ascertained by hospital discharge claims and estimated using Cox proportional hazard models. Propensity score (PS) matching was also used to adjust for significant differences in the baseline characteristics between the two groups. RESULTS: Overall, 1921 diabetic patients were included: 744 intermediate/long-acting HI and 1177 glargine users. During the 3-year follow-up, 209 (28.1%) incident events of any diabetic complication occurred in the intermediate/long-acting HI and 159 (13.5%) in the glargine group. After adjustment for covariates, glargine users had an HR (95% CI) of 0.57 (0.44-0.74) for any diabetic complication and HRs of 0.61 (0.44-0.84), 0.58 (0.33-1.04) and 0.35 (0.18-0.70) for macrovascular, microvascular and metabolic complications, respectively, compared to intermediate/long-acting HI users. PS analyses supported these findings. CONCLUSIONS: The use of glargine is associated with a lower risk of macrovascular complications compared with traditional basal insulins. However, limitations inherent to the study design including the short length of observation and the lack of data on metabolic control or diabetes duration, do not allow us to consider this association as a proof of causality.


Subject(s)
Diabetes Complications/epidemiology , Diabetes Mellitus, Type 2/drug therapy , Insulin, Long-Acting/therapeutic use , Adult , Aged , Aged, 80 and over , Diabetes Complications/prevention & control , Female , Follow-Up Studies , Humans , Incidence , Insulin Glargine , Italy/epidemiology , Longitudinal Studies , Male , Middle Aged , Proportional Hazards Models , Retrospective Studies , Risk Factors , Treatment Outcome
6.
Minerva Urol Nefrol ; 43(2): 117-20, 1991.
Article in Italian | MEDLINE | ID: mdl-1957229

ABSTRACT

NAG-urinary activity was assessed in order to study the renal effects of arterial hypertension in pregnant women. The results obtained showed that there were no significant differences between mean levels of enzymuria in control subjects and normotensive pregnant women. On the contrary, significant differences were found between these two groups and hypertensive pregnant women (above all if arterial hypertension predated pregnancy). The paper stresses the usefulness of this method, which is reliable and non-invasive, for an accurate assessment of the extent of renal damage caused by arterial hypertension during the course of pregnancy.


Subject(s)
Acetylglucosaminidase/urine , Hypertension/urine , Pre-Eclampsia/urine , Pregnancy Complications, Cardiovascular/urine , Proteinuria/urine , Adult , Female , Humans , Hypertension/complications , Kidney/physiopathology , Kidney Function Tests , Middle Aged , Pregnancy , Proteinuria/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...